Cargando…
Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways
Cisplatin is clinically proven to combat different cancers, including sarcomas, soft tissue cancers, bones, muscles, and blood. However, renal and cardiovascular toxicities are important limitations in cisplatin therapeutical use. Immunoinflammation could be key factor in cisplatin‐induced toxicity....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331131/ https://www.ncbi.nlm.nih.gov/pubmed/37424158 http://dx.doi.org/10.1002/prp2.1108 |